P84 High dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausal breast cancer patients (PTS). A prospective randomized trial
β Scribed by E. Galligioni; G. Cetto; O. Nascimben; A. Buonadonna; D. Crivellari; A. Molino; A. Veronesi; C. Graiff; S. Barni; C. Puccetti; E. Ferrazzi; E. Recaldin; C. Sava; S. Saracchini; C. Sacco
- Book ID
- 117665519
- Publisher
- Elsevier Science
- Year
- 1998
- Tongue
- English
- Weight
- 151 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Tenfour patients were treated with NFL: mitoxantrone 12 mg/m 2 IV on Day 1; leuconessee. vorin 300 mg IV over 30-60 minutes on Days 1, 2, and 3, immediately preceding
A prospective randomized study was conducted to compare the adjuvant efficacy of six cycles of high-dose ACMF (Adriamycin, ADM; cyclophosphamide, CPA; methotrexate, MTX; 5-fluorouracil, 5-FU) with that of 12 cycles of low-dose ACMF in premenopausal, node-positive breast cancer patients. The six-cycl